IART vs. ITGR, ATEC, ATRC, OFIX, SRDX, ANGO, ARAY, RMTI, RSLS, and ABT
Should you be buying Integra LifeSciences stock or one of its competitors? The main competitors of Integra LifeSciences include Integer (ITGR), Alphatec (ATEC), AtriCure (ATRC), Orthofix Medical (OFIX), Surmodics (SRDX), AngioDynamics (ANGO), Accuray (ARAY), Rockwell Medical (RMTI), ReShape Lifesciences (RSLS), and Abbott Laboratories (ABT). These companies are all part of the "health care equipment" industry.
Integra LifeSciences vs. Its Competitors
Integra LifeSciences (NASDAQ:IART) and Integer (NYSE:ITGR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.
In the previous week, Integer had 3 more articles in the media than Integra LifeSciences. MarketBeat recorded 11 mentions for Integer and 8 mentions for Integra LifeSciences. Integer's average media sentiment score of 1.19 beat Integra LifeSciences' score of 1.03 indicating that Integer is being referred to more favorably in the news media.
Integra LifeSciences currently has a consensus price target of $18.43, suggesting a potential upside of 21.80%. Integer has a consensus price target of $140.25, suggesting a potential upside of 32.64%. Given Integer's stronger consensus rating and higher probable upside, analysts plainly believe Integer is more favorable than Integra LifeSciences.
Integer has higher revenue and earnings than Integra LifeSciences. Integra LifeSciences is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.
Integer has a net margin of 4.61% compared to Integra LifeSciences' net margin of -30.87%. Integer's return on equity of 12.27% beat Integra LifeSciences' return on equity.
84.8% of Integra LifeSciences shares are owned by institutional investors. Comparatively, 99.3% of Integer shares are owned by institutional investors. 3.5% of Integra LifeSciences shares are owned by insiders. Comparatively, 2.2% of Integer shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Integra LifeSciences has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Integer has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500.
Summary
Integer beats Integra LifeSciences on 15 of the 17 factors compared between the two stocks.
Get Integra LifeSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for IART and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IART and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Integra LifeSciences Competitors List
Related Companies and Tools
This page (NASDAQ:IART) was last updated on 9/4/2025 by MarketBeat.com Staff